3-V Biosciences

3-V Biosciences is a privately held biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. 3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today.
Company Growth (employees)
Type
Private
HQ
Menlo Park, US
Founded
2007
Size (employees)
12 (est)-7%
Website
3vbio.com
3-V Biosciences was founded in 2007 and is headquartered in Menlo Park, US

Key People/Management at 3-V Biosciences

Sara Nayeem

Sara Nayeem

Investor
George Kemble

George Kemble

Chief Scientific Officer
Richard Klausner

Richard Klausner

Former Director
Douglas I Buckley,

Douglas I Buckley,

Vice President, Biology

3-V Biosciences Office Locations

3-V Biosciences has an office in Menlo Park
Menlo Park, US (HQ)
1050 Hamilton Ct

3-V Biosciences Financials and Metrics

Summary Metrics

Founding Date

2007

Total Funding

$119.6 m

Latest funding size

$5.4 m

Time since last funding

over 1 year

Investors

3-V Biosciences's latest funding round in July 2016 was reported to be $5.4 m. In total, 3-V Biosciences has raised $119.6 m

3-V Biosciences's Web-traffic and Trends

3-V Biosciences Company Life and Culture

You may also be interested in